Granules packaging facility completes U.S. FDA inspection sans observations
[ad_1] Generic drugmaker Granules India’s packaging facility in the U.S. completed a GMP inspection by the U.S. Food and Drug Administration (FDA) with zero observations. This was second U.S. FDA inspection of Granules Consumer Health facility’s and follows the March 2023 audit that resulted in a no action indicated (NAI) classification by the regulator, Granules […]
Continue Reading